» 
PharmNovo attending LSX 3–4 May
Copy URL
https://www.pharmnovo.com/post/pharmnovo-attending-lsx-3-4-may

PharmNovo attending LSX 3–4 May

May 2, 2023

PharmNovo will participate in the LSX World Congress in London, 3-4 May. Our CEO, Per von Mentzer, will present PharmNovo and the latest progress in the ongoing clinical trial of our innovative new drug candidate for neuropathic pain, PN6047.

"There is a huge need for safe and effective drugs for people suffering from neuropathic pain. Our drug candidate PN6047 has a novel mode of action that avoids the unwanted side effects of current treatments. I will be sharing the latest progress in the ongoing Phase I clinical trial and discuss the design of our upcoming Phase IIa studies planned for next year," says Per von Mentzer, CEO at PharmNovo.

Per von Mentzer is presenting on 4 May, at 10:45 at Showcase Biotech.

The LSX World Congress is Europe's leading partnering, strategy, and investment event for life science and executive leaders. To learn more about LSX and explore the agenda for the world congress, visit: https://lnkd.in/eZUDkZSv

Petra Larson
Author:
Petra Larson
Copy URL
https://www.pharmnovo.com/post/pharmnovo-attending-lsx-3-4-may

PharmNovo attending LSX 3–4 May

May 2, 2023

PharmNovo will participate in the LSX World Congress in London, 3-4 May. Our CEO, Per von Mentzer, will present PharmNovo and the latest progress in the ongoing clinical trial of our innovative new drug candidate for neuropathic pain, PN6047.

"There is a huge need for safe and effective drugs for people suffering from neuropathic pain. Our drug candidate PN6047 has a novel mode of action that avoids the unwanted side effects of current treatments. I will be sharing the latest progress in the ongoing Phase I clinical trial and discuss the design of our upcoming Phase IIa studies planned for next year," says Per von Mentzer, CEO at PharmNovo.

Per von Mentzer is presenting on 4 May, at 10:45 at Showcase Biotech.

The LSX World Congress is Europe's leading partnering, strategy, and investment event for life science and executive leaders. To learn more about LSX and explore the agenda for the world congress, visit: https://lnkd.in/eZUDkZSv

Petra Larson
Author:
Petra Larson

Latest news

View all
March 21, 2024

Positive final Phase I results

The final results from the Phase I clinical for our neuropathic pain drug candidate PN6047, demonstrates safety and tolerability and a lack of the adverse effects commonly associated with conventional opioids. The findings from the Phase I trial show that PN6047 is safe and well-tolerated at the doses tested, with no serious adverse events reported.

Read more
March 10, 2024

Visionaries in pain relief: PharmNovo presents Bengt von Mentzer, founder and Chief scientific advisor.

Bengt von Mentzer founded PharmNovo 16 years ago, and today, his visionary approach and scientific process still drive the development of the groundbreaking compound PN6047. At the intersection of innovation and scientific leadership, Bengt von Mentzer is paving the way for how to reshape the landscape of chronic pain treatment.

Read more
January 30, 2024

NIDA funds studies

The US National Institute of Drug Abuse (NIDA) has funded a project investigating the drug candidate PN6047, a novel and highly selective Delta Opioid Receptor Agonist (DORA), represents a unique approach to addressing this medical challenge.

Read more
January 30, 2024

Meet Olof Breuer, MD, Clinical pharmacology lead

Olof Breuer's presence at PharmNovo exemplifies the company's commitment to pioneering advancements in pain relief. His visionary approach, honed through years of experience, positions him as a driving force in the quest for novel concepts in neuropathic pain relief.

Read more